EP2119696A1 — Preparation of O-desmethylvenlafaxine salts
Assigned to KRKA dd · Expires 2009-11-18 · 16y expired
What this patent protects
The present invention relates to a process for the preparation of a salt of O-desmethylvenlafaxine comprising a) dissolving or suspending O-desmethylvenlafaxine in the form of its base in a liquid medium selected from the group of solvents and suspending agents; b) contacting O…
USPTO Abstract
The present invention relates to a process for the preparation of a salt of O-desmethylvenlafaxine comprising a) dissolving or suspending O-desmethylvenlafaxine in the form of its base in a liquid medium selected from the group of solvents and suspending agents; b) contacting O-desmethylvenlafaxine with a pharmaceutically acceptable acid to form a pharmaceutically acceptable salt of O-desmethylvenlafaxine wherein the pharma-ceutically acceptable acid is selected from the group consisting of maleic acid, citric acid, tartaric acid and L-aspartic acid, optionally filtering the solution; and c) separating the pharmaceutically acceptable salt of O-desmethylvenlafaxine from the liquid medium to recover the salt, and to pharmaceutical formulations containing these salts.
Drugs covered by this patent
- Pristiq (Desvenlafaxine Succinate) · Pfizer
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.